Qualigen Therapeutics Inc (QLGN) |
|
2.88 -0.02 (-0.69%)
|
03-07 04:36 |
|
Open: |
2.96 |
Pre. Close: |
2.9 |
|
High:
|
2.98 |
Low:
|
2.562 |
|
Volume:
|
1,621,303 |
Market Cap:
|
77M |
|
|
|
|
Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.984 - 3.005 |
3.005 - 3.021 |
|
Low:
|
2.512 - 2.537 |
2.537 - 2.556 |
|
Close:
|
2.842 - 2.879 |
2.879 - 2.908 |
|
Technical analysis |
as of: 2021-03-05 5:12:24 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 4.34  One year: 5.18 |
| Support: |
Support1: 2.56 Support2: 2.13 |
| Resistance: |
Resistance1: 3.72 Resistance2: 4.43 |
| Pivot: |
3.57 |
| Moving Average: |
MA(5): 3.14 MA(20): 3.69
MA(100): 3.67 MA(250): 5.29 |
| MACD: |
MACD(12,26): -0.16 Signal(9): -0.04 |
| Stochastic oscillator: |
%K(14,3): 7.48  %D(3): 7.95 |
| RSI: |
RSI(14): 31.80 |
| 52-week: |
High: 19.75 Low: 2.56 Change(%): -68.0 |
| Average Vol(K): |
3-Month: 203873 10-Days: 116199 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.QLGN has closed above bottom band by 7.4%. Bollinger Bands are 72.8% wider than normal. The large width of the bands suggest high volatility as compared to QLGN's normal range. The bands have been in this wide range for 1 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Fri, 05 Mar 2021
The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study - Yahoo Finance
Mon, 01 Mar 2021
Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL - GlobeNewswire
Wed, 10 Feb 2021
Does Qualigen Therapeutics Inc (QLGN) Have What it Takes to be in Your Portfolio? - InvestorsObserver
Tue, 09 Feb 2021
Is Qualigen Therapeutics Inc (QLGN) Stock Worth a Buy Tuesday? - InvestorsObserver
Mon, 08 Feb 2021
Should You Buy Qualigen Therapeutics Inc (QLGN) Stock on Monday? - InvestorsObserver
Wed, 27 Jan 2021
Should You Buy Qualigen Therapeutics Inc (QLGN) Stock? - InvestorsObserver
|
Financial Analysis |
| Growth |
NA |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
NA |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
NA |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
NA |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Underperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Outperform |
Debt to Equity: |
Underperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
27 |
| Shares Float (M) |
21 |
|
% Held by Insiders
|
10.91 |
|
% Held by Institutions
|
3.12 |
|
Shares Short (K)
|
1,920 |
|
Shares Short P. Month (K)
|
1,750 |
Stock Financials |
|
EPS
|
|
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
|
|
Profit Margin
|
|
|
Operating Margin
|
-152.04 |
|
Return on Assets (ttm)
|
|
|
Return on Equity (ttm)
|
|
|
Qtrly Rev. Growth
|
-30.3 |
|
Gross Profit (p.s.)
|
0.014 |
|
Sales Per Share
|
0.172 |
|
EBITDA (p.s.)
|
-0.255 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-7 |
|
Levered Free Cash Flow (M)
|
|
Stock Valuations |
|
PE Ratio
|
|
|
PEG Ratio
|
|
|
Price to Book value
|
|
|
Price to Sales
|
16.76 |
|
Price to Cash Flow
|
-11.26 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
